Those who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return ...

Over the last five years, the industry has traded as high as 20.80X, as low as 12.92X and at a median of 15.13X, as the chart ... Humira, are declining due to loss of exclusivity and biosimilar ...

The drug and biotech sector has recovered over the past couple of months, following a slow start to the year, primarily due ...

Co-production deals with adalimumab biosimilar manufacturers and PBMs have increased biosimilar adoption, but this ...

Opens in a new tab or window Uncertainties remain about the real-world benefit of adalimumab biosimilars for psoriasis, limiting their widespread adoption. This analysis involving patients in the ...

Sandoz pointed to the uptake of its Humira biosimilar Hyrimoz in the US through a private-label agreement with CVS biosimilar subsidiary Cordavis as one of the drivers of its biosimilar business ...

After years of patent protection, biosimilars for Humira are set to enter the US market in 2023. The arrival of these drugs has been widely anticipated throughout the healthcare industry.

European regulators have backed a new Humira biosimilar for approval, setting up a four-way race for the blockbuster’s market share later this year between Amgen, Boehringer Ingelheim ...

CVS Caremark, Express Scripts and Optum Rx — the three largest pharmacy benefit managers in the U.S. — each excluded more ...

Rising biosimilar adoption, shifting market dynamics, and escalating supply chain vulnerabilities are driving change in ...

Successful launches of biosimilars to HUMIRA and STELARA are key revenue drivers. Alvotech’s business-to-business model facilitates global reach, with one-third of revenues from ex-U.S. markets.